Interview with founder and CEO Gilad Almogy of Ultima Genomics discussing their solutions in the field of DNA sequencing.
**Ultima Genomics Revolutionizes Genomic Sequencing Under CEO Gilad Almogy**
Ultima Genomics, a trailblazing biotech company, is making significant strides in revolutionizing genomic sequencing, under the leadership of its founder and CEO, Gilad Almogy, Ph.D. The company is dedicated to enabling large-scale biological and health research advancements by dramatically reducing the cost of genomic sequencing and scaling up its throughput.
As a scientist with a Ph.D., Almogy is actively engaged in pushing the boundaries of sequencing technology and its applications in genomics. As CEO, he leads Ultima Genomics in its mission to make genomic sequencing more affordable and powerful, leveraging the convergence of several cutting-edge technologies, such as single-cell genomics, AI, CRISPR, and perturbation methods.
The company's core product, the UG 100 Sequencing Platform, is an ultra-high-throughput, next-generation sequencing system. This innovative platform, introduced in February 2024, supports ultra-high throughput sequencing at reduced costs, enabling population-scale studies that were previously infeasible due to expense or technological limitations.
One of the key advancements in the UG 100 Sequencing Platform is the Solaris technology, which was introduced in February 2025, one year after the commercial launch of the UG 100. Solaris increased system output by more than 50% and lowered the cost for customers to $80 per genome. Moreover, Solaris enables the sequencer to generate between 10-12 billion reads per wafer, or 20-24 billion reads per dual-wafer run.
Ultima Genomics has also introduced an ultra-high throughput mode called Boost, which doubles the already significant sequencer output for several key applications. This technology allows the sequencer to run 4 wafers per day, 24/7, and over the weekend, or generate 120 whole genomes or more than 2 million cells for single-cell RNA sequencing in a day.
The company's technology has been selected for major large-scale proteomics studies, including collaborations with the Regeneron Genetics Center and the UK Biobank Pharma Proteomics Project, highlighting the platform's capabilities in handling massive sample volumes efficiently. Ultima's innovative sequencing architecture aims to overcome trade-offs in breadth, depth, and frequency of genomic data use, which are key hurdles for scientists and clinicians working with genomic information.
Ultima Genomics has raised over $700 million from leading investors to build and commercialize its technology platform. The company has established strong collaborations with leading technology developers to build workflows that generate rich, high-content datasets necessary to power emerging AI models in biology. AI is expected to allow for modeling the cell in all its complexity, potentially having a significant impact on drug discovery, precision medicine, and cellular and molecular biology.
In summary, Gilad Almogy leverages his scientific expertise and visionary leadership to drive Ultima Genomics’ development of cost-efficient, scalable sequencing technologies that enable transformative advances in genomics research and healthcare. The company's UG 100 Sequencing Platform, built around a unique open-flow cell architecture using a semiconductor wafer and ultra-fast chemistry, supports a wide range of large-scale sequencing applications, including liquid biopsy, whole-genome sequencing, single-cell RNA sequencing, methylation analysis, and proteogenomics. Ultima Genomics' focus remains on continuing to scale throughput, lower costs, and expand into new applications, with a particular emphasis on enabling the BioAI movement.
- Gilad Almogy, with his expertise in science and leadership as CEO, is driving Ultima Genomics to revolutionize the field of medical-conditions, focusing on health-and-wellness through advanced genomic sequencing technology.
- Ultima Genomics' mission is to make genomic sequencing affordable, powerful, and scalable, using a combination of innovative technologies such as single-cell genomics, artificial-intelligence, CRISPR, and perturbation methods.
- The company's flagship product, the UG 100 Sequencing Platform, introduced in February 2024, offers ultra-high-throughput next-generation sequencing at reduced costs, making large-scale health research more accessible.
- In February 2025, Ultima Genomics launched the Solaris technology, boosting system output by more than 50% and reducing costs to $80 per genome, while generating an impressive number of reads per wafer.
- Ultima Genomics has also developed the ultra-high throughput mode called Boost, which doubles the sequencer output and allows for the sequencing of over 120 whole genomes or more than 2 million cells for single-cell RNA sequencing in a day.
- The company's technology is being used in major large-scale proteomics studies, showcasing its potential in handling massive sample volumes efficiently. This capability is crucial for powering emerging AI models in biology, which could have a significant impact on fields such as drug discovery, precision medicine, and cellular and molecular biology.
